Canopy Growth Reports Mixed Quarterly Results: Domestic Strength Offsets International Headwinds

Canopy Growth reports flat revenue at $75M but cuts net loss by 49%. Canadian medical & recreational sales rise, offset by a 31% drop in international revenue and vaporizer segment weakness.

Canopy Growth Corporation has released its financial results for the third quarter of fiscal year 2026, revealing a company performing on two distinct tracks. While its core Canadian operations showed robust health, challenges in international markets and its vaporizer segment weighed on overall progress.

Financial Performance and Loss Reduction

For the quarter, the cannabis producer reported total revenue holding steady at $75 million, unchanged from the same period last year. A significant bright spot was the notable 49% year-over-year reduction in its net loss. The company also posted its third consecutive quarter of improvement in adjusted EBITDA loss, which narrowed to $3 million. Management attributed this progress primarily to reductions in selling, general, and administrative expenses. Canopy's liquidity position remains solid, with $371 million in cash and a net cash position of $146 million.

A Tale of Two Markets: Canada vs. International

Beneath the flat top-line figure, divergent stories emerged across different geographic segments. In Canada, cannabis revenue demonstrated solid growth. Medical cannabis sales increased by 15% to $23 million, driven by a larger base of patients covered by insurance and higher order volumes. The recreational business also grew by 8%, fueled by new product formats such as infused pre-rolls and all-in-one vapes under the Tweed, 7ACRES, and Claybourne brands.

This domestic strength was counterbalanced by significant international weakness. Revenue from outside Canada contracted sharply by 31%, which the company linked primarily to supply chain disruptions in Europe. Furthermore, the Storz & Bickel vaporizer segment saw a 9% decline in sales, pressured by a difficult prior-year comparison and ongoing consumer spending caution.

Strategic Moves: Acquisitions, Debt, and New Brands

On the strategic front, Canopy Growth completed its acquisition of MTL Cannabis in March 2026. The company now describes the combined entity as Canada's leading medical cannabis business by revenue. The transaction involved the issuance of approximately 41.2 million new Canopy shares and a cash payment of about $18.5 million. Management expects to realize synergies of roughly $10 million within 18 months, with a target of achieving positive adjusted EBITDA in fiscal year 2027.

Concurrently, the company restructured its debt in January 2026, extending all maturities to at least January 2031. This restructuring included a new loan that provided net proceeds of $150 million (USD) and the exchange of approximately $96.4 million (CAD) in debentures for new convertible notes.

To compete in the value segment of the consumer market, Canopy launched a new brand called Deelish. The brand focuses on cost-conscious consumers, offering flower products with THC concentrations ranging from 27% to 33%. Deelish employs a strategy of regularly rotating its strain offerings in an attempt to differentiate itself within the highly competitive recreational landscape.

Analyst Sentiment and the Road Ahead

Market analysts maintain a cautious stance. The average 12-month price target for the stock on the TSX is $2.383 (CAD). Current ratings include two "buy" recommendations, one "sell" recommendation, and an overall "neutral" consensus. Analysts continue to cite concerns such as declining overall revenue, persistent net losses, and negative cash flow.

The next significant milestone will be the annual results in May 2026. CEO Luc Mongeau has indicated that more detailed strategic plans will be presented at that time, offering investors clearer evidence of whether the integration of MTL and the new value-brand strategy are translating into tangible financial improvement.